To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

PDS and RTI International Collaboration

With funding support from the Robert Wood Johnson Foundation, Project Data Sphere (PDS) and RTI International collaborated to enhance the analytical utility of selected datasets hosted on the PDS platform.

Based on Patient Reported Outcomes data captured in the EQ-5D™ index score (derived from the EuroQOL five dimensions questionnaire), RTI identified likely corresponding socio-demographic, access, health, and healthcare related variables captured from the Medical Expenditure Panel Survey (MEPS). These variables include:

Socio-demographic factors: Age, race/ethnicity, sex, marital status, employment status, education level, income level, year in MEPS
Access related factors: Insurance coverage, ability to obtain necessary medical care
Health related: EQ5D, health status, work limitations, smoker status
Healthcare related: Office based physician visits, in-patient stays, ER visits, Rx purchases, total expenditures

Follow the links in the table below to view the data. You may view background information about each dataset without logging in; to view and download the dataset you must Apply for Access or Login if you are already an Authorized User.

Supporting documents with additional information has been provided for each dataset. To access the MEPS data, please visit this link.

Original Patient-Level Dataset

Enhanced RTI Dataset

A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer

Enhancing the Analytic Capacity of Prostate_Celgene_2009_90 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic

Enhancing the Analytic Capacity of Prostat_AstraZe_2009_144 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

A Randomized, Double-blind, Multicenter Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer

Enhancing the Analytic Capacity of Colorec_AstraZe_2006_78 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

A randomized, open-label, Phase 3 study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda) tablets twice daily for 2 weeks in 3-week cycles in patients with metastatic breast cancer progressing after taxanes and anthracycline therapy (EFC6089)

Enhancing the Analytic Capacity of Breast_SanofiU_2004_135 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

D4320C00015: A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients

Enhancing the Analytic Capacity of Prostat_AstraZe_2008_103 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

D4320C00033. A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer

Enhancing the Analytic Capacity of Prostat_AstraZe_2008_104 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

Open label, randomized multicenter Phase II/III study of Docetaxel in combination with Cisplatin or Docetaxel in combination with 5-Fluorouracil and Cisplatin compared to the combination of Cisplatin and 5-Fluorouracil in patients with metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease.

Enhancing the Analytic Capacity of Gastric_SanofiU_1999_143 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction

Enhancing the Analytic Capacity of Gastric_MerckKG_2008_130 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey

START - Stimulating Targeted Antigenic Responses To NSCLC. A multi-center phase III randomized, double-blind placebocontrolled study of the cancer vaccine Stimuvax? (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease

Enhancing the Analytic Capacity of LungNo_MerckKG_2007_145 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey